Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 14/20 | 0.58 |
| ▸ | ERBB2 | P04626 | 13/20 | 0.58 |
| ▸ | ERBB4 | Q15303 | 10/20 | 0.58 |
| ▸ | JAK3 | P52333 | 12/20 | 0.56 |
| ▸ | BTK | Q06187 | 5/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6495848 | 0.93 | EGFR (0.57) | EGFRERBB2ERBB4JAK3BTK | |
| SCHEMBL6493953 | 0.91 | EGFR (0.51) | EGFRERBB2ERBB4JAK3BTK | |
| SCHEMBL6482142 | 0.86 | ERBB2 (0.59) | EGFRERBB2ERBB4JAK3 | |
| SCHEMBL6483285 | 0.85 | EGFR (0.49) | EGFRERBB2ERBB4JAK3BTK | |
| SCHEMBL6484263 | 0.83 | EGFR (0.59) | EGFRERBB2ERBB4JAK3BTK | |
| SCHEMBL6485873 | 0.82 | JAK3 (0.54) | EGFRERBB2ERBB4JAK3BTK | |
| SCHEMBL6482672 | 0.81 | ERBB2 (0.62) | EGFRERBB2ERBB4JAK3BTK | |
| SCHEMBL6492412 | 0.79 | ERBB2 (0.67) | EGFRERBB2ERBB4JAK3BTK | |
| SCHEMBL6491159 | 0.78 | ERBB2 (0.52) | EGFRERBB2ERBB4JAK3 | |
| SCHEMBL6484196 | 0.77 | JAK3 (0.65) | EGFRERBB2ERBB4JAK3BTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6881737-B2 | Substituted triazinyl acrylamide derivatives and methods of use | AMGEN INC. (US) | 2005-04-19 | — | — | US | claimed |
| EP-1390354-A1 | TRIAZINYL ACRYLAMIDE DERIVATIVES AS KINASE INHIBITORS | Amgen Inc. (US) | 2004-02-25 | — | — | EP | claimed |
| US-20030139416-A1 | Substituted triazinyl acrylamide derivatives and methods of use | AMGEN INC. | 2003-07-24 | — | — | US | claimed |
| WO-2002083653-A1 | TRIAZINYL ACRYLAMIDE DERIVATIVES AS KINASE INHIBITORS | AMGEN INC. (US) | 2002-10-24 | — | — | WO | claimed |
| US-20050176700-A1 | 7-aryl-3,9-diazabicyclo(3.3.1)non-6-ene derivatives and their use as renin inhibitors in the treatment of hypertension,cardiovascular or renal diseases | ACTELION PHARMACEUTICALS LTD. (CH) | 2005-08-11 | — | — | US | disclosed |
| US-6881737-B2 | Substituted triazinyl acrylamide derivatives and methods of use | AMGEN INC. (US) | 2005-04-19 | — | — | US | disclosed |
| EP-1390354-A1 | TRIAZINYL ACRYLAMIDE DERIVATIVES AS KINASE INHIBITORS | Amgen Inc. (US) | 2004-02-25 | — | — | EP | disclosed |
| US-20030139416-A1 | Substituted triazinyl acrylamide derivatives and methods of use | AMGEN INC. | 2003-07-24 | — | — | US | disclosed |
| WO-2002083653-A1 | TRIAZINYL ACRYLAMIDE DERIVATIVES AS KINASE INHIBITORS | AMGEN INC. (US) | 2002-10-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030139416-A1 | Substituted triazinyl acrylamide derivatives and methods of use | PKD1, PKD2, GLS | EGFR 228/4885ERBB2 440/4885ERBB4 798/4885 |
| US-20050176700-A1 | 7-aryl-3,9-diazabicyclo(3.3.1)non-6-ene derivatives and their use as renin inhibitors in the treatment of hypertension,cardiovascular or renal diseases | REN, AGTR1, ACE | EGFR 1776/4885ERBB2 2073/4885ERBB4 2295/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.